- Conditions
- Epithelial Ovarian Cancer
- Interventions
- MUC1 Dendritic Cell Vaccine (Cvac)
- Biological
- Lead sponsor
- Prima BioMed Ltd
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 5
- States / cities
- Greenbrae, California • La Jolla, California • Boca Raton, Florida + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 2,050
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder Cancer, Prostate Cancer, Testicular Cancer, Bladder Carcinoma, Genitourinary System Carcinoma, Malignant Testicular Neoplasm, Melanoma, Prostate Carcinoma, Sarcoma
- Interventions
- Blood and Tissue
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Ovarian Neoplasm
- Interventions
- KU-0059436 (AZD2281)(PARP inhibitor)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
- Conditions
- Radiation Therapy, Cancer, Cancer of Anus, Cancer of Bladder, Cancer of Cervix, Cancer of Colon, Cancer of Rectum, Cancer of Esophagus, Cancer of Gallbladder, Cancer of Liver, Cancer of Ovary, Cancer of Pancreas, Cancer of Prostate, Cancer of Kidney and Renal Pelvis, Cancer of Stomach, Cancer of Testis, Cancer of Uterus, Cancer of Uterus and Cervix, Cancer of Kidney
- Interventions
- Not listed
- Lead sponsor
- DxTerity Diagnostics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Compton, California • Bradenton, Florida • Fort Myers, Florida + 1 more
- Conditions
- Anxiety Disorder, Cervical Cancer, Endometrial Cancer, Female Reproductive Cancer, Gestational Trophoblastic Tumor, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Sexual Dysfunction, Uterine Sarcoma, Vaginal Cancer, Vulvar Cancer
- Interventions
- informational intervention, counseling intervention, questionnaire administration
- Other
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- carboxyamidotriazole, chemotherapy
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- carboplatin, docetaxel, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Floyd & Delores Jones Cancer Institute at Virginia Mason Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Ovarian Cancer
- Interventions
- Doxil (Pegylated Liposomal Doxorubicin), BIBF 1120
- Drug
- Lead sponsor
- Hoosier Cancer Research Network
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Madison, Wisconsin
- Conditions
- Tumor Pathway Activations Inhibited by Dovitinib
- Interventions
- Dovitinib (TKI258)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Pismo Beach, California + 43 more
- Conditions
- Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal Cancer, Lung Cancer, Prostate Cancer, Breast Cancer
- Interventions
- QXL138AM Injection every 2 weeks by IV Infusion
- Biological
- Lead sponsor
- Nammi Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Newport, California • Denver, Colorado + 5 more
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Placebo, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 614
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 395 more
- Conditions
- Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Sorafenib Tosylate
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine, Laboratory Biomarker Analysis, Poly ICLC
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Duarte, California • Sacramento, California + 11 more
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasms
- Interventions
- Pegylated L-Asparaginase
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Cancer, Endometrial Cancer, Colo-rectal Cancer, Cholangiocarcinoma, Non-small Cell Lung Cancer, Pancreas Cancer
- Interventions
- Not listed
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Polycystic Ovarian Syndrome
- Interventions
- Flax Seed Oil, Fish Oil, Soybean Oil
- Dietary Supplement
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Anovulation
- Interventions
- Anastrozole 1 mg, Anastrozole 5 mg, Anastrozole 10 mg, Clomiphene Citrate 50 mg, Clomiphene Citrate 100 mg
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 271 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Solid Tumors
- Interventions
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Drug
- Lead sponsor
- DualityBio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Wheat Ridge, Colorado • Florida City, Florida + 11 more
- Conditions
- Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
- Interventions
- CARES Intervention
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 14
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Fort Collins, Colorado + 8 more
- Conditions
- Advanced Malignancies, Metastatic Cancer
- Interventions
- INCAGN01876, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- Incyte Biosciences International Sàrl
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Gainesville, Florida • Detroit, Michigan + 12 more
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Pembrolizumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Minneapolis, Minnesota • Rochester, Minnesota
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Leukemia, Lymphoma, Ovarian Cancer
- Interventions
- melphalan
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2001
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Malignant Mesothelioma, Ovarian Cancer, Pancreatic Cancer, Primary Peritoneal Cavity Cancer
- Interventions
- SS1(dsFv)-PE38 immunotoxin
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- Salsalate
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 47 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana